Eli Lilly (NYSE:LLY) yesterday dosed the first patient in a trial of its automated insulin delivery system.
The system is a hybrid closed-loop platform that includes a connected insulin pump, a dosing algorithm and a continuous glucose monitor.
Get the full story at our sister site, Drug Delivery Business News.
The post Lilly launches trial for automated insulin delivery system appeared first on MassDevice.